COMPASS Pathways plc

COMPASS Pathways plc (CMPS) priced its initial public offering on Sep 21, 2020 at $17.00 per ADS, above its $14.00–$16.00 range, raising $127.5M, and listed on Nasdaq Global Select. At the IPO price its market capitalization was about $591.7M. TD Cowen was lead-left underwriter, joined by Evercore ISI, Canaccord Genuity and H.C. Wainwright. Goodwin Procter advised the company and Cooley advised the underwriters.

COMPASS Pathways plc is a mental health care company developing a model of psilocybin therapy, in which psilocybin is given together with psychological support. Its initial focus is treatment-resistant depression, a subset of major depressive disorder.

Status

IPO

Ticker

CMPS

Exchange

Nasdaq Global Select

Priced

Sep 21, 2020

IPO price

$17.00 per ADS

Price range

$14.00–$16.00

Raised

$127.5M

Market cap at IPO price

$591.7M

First filed

Aug 28, 2020

Underwriters

TD Cowen, Evercore ISI, Canaccord Genuity and H.C. Wainwright

Company counsel

Goodwin Procter

Underwriters' counsel

Cooley

Sector

Biotech & pharma

Country / state

United Kingdom

Market cap at IPO price = shares outstanding after the offering (all classes, before the over-allotment option) × the IPO price, from the final prospectus.